ZoneOne Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ZoneOne Pharma is a clinical-stage biotech leveraging deep expertise in liposomal drug delivery to develop next-generation topical treatments for chronic inflammatory skin disorders. The company's proprietary platform aims to improve drug delivery, efficacy, and patient compliance over existing standards of care. With a leadership team comprised of veterans from the liposomal field, including co-inventors of major approved products like DOXIL and Onivyde, Z1P is advancing a pipeline from preclinical development. The company operates as a private, pre-revenue entity, likely funded through grants and venture capital, and is strategically positioned in the large and growing dermatology therapeutics market.

Dermatology

Technology Platform

Proprietary liposomal and nanomedicine delivery platform for topical application, designed to enhance drug penetration, provide sustained release, and improve patient compliance in treating chronic inflammatory skin diseases.

Opportunities

The large and growing global market for dermatology therapeutics, particularly chronic inflammatory diseases like psoriasis and eczema, presents a significant commercial opportunity.

ZoneOne's liposomal platform could address key unmet needs for safer, more effective, and more convenient topical therapies with improved compliance.

Successful clinical validation could also enable platform expansion into other localized inflammatory conditions.

Risk Factors

Key risks include technical failure of the liposomal platform to demonstrate clinical superiority, challenges in scaling manufacturing of complex nanomedicines, and regulatory hurdles specific to novel drug delivery systems.

As a pre-revenue private company, ZoneOne also faces significant financing risk and operates in a highly competitive dermatology market dominated by large pharma.

Competitive Landscape

ZoneOne competes in the crowded dermatology space against large pharmaceutical companies with extensive portfolios (e.g., AbbVie, Pfizer, Leo Pharma) and numerous biotechs developing both topical and systemic therapies. Its differentiation hinges on its liposomal delivery technology, aiming to outperform standard topical formulations (e.g., creams, ointments) in efficacy and convenience rather than competing on novel drug targets alone.

More companies in Small Molecule Drugs →More companies in United States →